
Why the Administration Should Be Flexible with Medtech Tariffs to Protect Patients and Innovation
Flexibility on tariffs is critical to maintaining medtech as the backbone of the U.S. health care system and an American economic success story.
AdvaMed®’s Medtech POV blog features all the latest developments, perspectives, and resources by and for the medical technology community.
Flexibility on tariffs is critical to maintaining medtech as the backbone of the U.S. health care system and an American economic success story.
AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.
Nominate a medtech pioneer for AdvaMed®’s 2025 Lifetime Achievement Award to celebrate their contributions to the health care industry!
We took time to reflect on another extraordinary year in the medtech industry and the tremendous strides we’ve made together. Our 2024 AdvaMed® Annual Report highlights our key policy wins,…
Brought to you by AdvaMed®, Medtech POV with Scott Whitaker is a podcast that covers the intersection of medtech and policy from every perspective.
AdvaMed® filed an amicus brief in the case of Smith v. Terumo BCT, Inc. The case concerns whether the court should create a cause of action for asymptomatic plaintiffs, permitting…
Recap AdvaMed®’s Medical Imaging Divisions achievements for members and the industry during its inaugural year with the medtech association.
This case involves a patent infringement dispute between EcoFactor and Google, but the Court’s decision will reach every aspect of district court patent litigation in cases involving parties in every…
Maria Artunduaga’s grandmother never smoked. However, like many members of her generation, she was exposed to second-hand cigarette smoke much of her life. When she developed chronic obstructive pulmonary disease…
If you have media inquiries, please contact:
Cody Uhing, Director, Communications & Media Relations, 202-316-1423
The issue at hand is patent infringement and an overly broad interpretation of the Hatch-Waxman Act’s safe harbor. AdvaMed® pointed out that this would harm innovation. The decision has profound…
Join over 500 medical technology companies as a member of one of the most effective trade associations in Washington, D.C.